Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools

Journal of Leukocyte Biology

Inge Tinhofer²  Gabriele Anether¹  Richard Greil²  Karin Johrer³ 

[1] Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and;Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Tyrolean Cancer Research Institute, Innsbruck, Austria Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Tyrolean Cancer Research Institute, Innsbruck, Austria Tyrolean Cancer Research Institute, Innsbruck, Austria Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Tyrolean Cancer Research Institute, Innsbruck, Austria;Tyrolean Cancer Research Institute, Innsbruck, Austria Tyrolean Cancer Research Institute, Innsbruck, Austria Tyrolean Cancer Research Institute, Innsbruck, Austria

关键词: lymphoma;    tumor counterattack;    novel therapeutic strategies;   

DOI  :  10.1189/jlb.0802416

学科分类：生理学

来源: Federation of American Societies for Experimental Biology

【 摘 要 】

In the past decade, it was concluded from a number of investigations that death domain-containing members of the tumor necrosis factor-receptor (TNF-R) family and their ligands such as Fas/FasL and TNF-related apoptosis-inducing ligand (TRAIL)-R/TRAIL are essential for maintaining an intact immune system for surveillance against infection and cancer development and that nondeath domain-containing members such as CD30 or CD40 are involved in the fine tuning of this system during the selection process of the lymphatic system. In line with this conclusion are the observations that alterations in structure, function, and regulation of these molecules contribute to autoimmunity and cancer development of the lymphoid system. Besides controlling size and function of the lymphoid cell pool, Fas/FasL and TRAIL-R/TRAIL regulate myelopoiesis and the dendritic cell functions, and severe alterations of these lineages during the outgrowth and expansion of the lymphoid tumors have been reported. It is the aim of this review to summarize what is currently known about the complex role of these two death receptor/ligand systems in normal, disturbed, and neoplastic hemato-/lymphopoiesis and to point out how such knowledge can be used in developing novel, therapeutic options and the problems that will have to be faced along the way.

【 授权许可】

Unknown